Kelly Nichols, Alcon (F), Allergan (C), Bruder (C), Kala (C), Kala (F), NIH NEI (F), Oyster Point (C), Pentavision (C), Science Based Health (C), Shire/Novartis (C), Sight Sciences (C), TearFilm Innovations/Alcon/Acquiom (C), TearScience (F), Tear Solutions (F), TopiVert (C);
John Hovanesian, Novartis (C), Novartis (F), Shire (C), Shire (F), Takeda (C), Takeda (F);
James Katz, Alcon (C), Allergan (C), Eyevance Pharmaceuticals (C), Kala (C), Legrande (C), Novartis (C), Ocular Science (C), Ocular Therapeutix (C), Sun Pharmaceutical Industries (C);
Annie Syntosi, Novartis Pharma AG (E);
Arthur Chan, Novartis Pharmaceuticals Corporation (E);
Mrudula Glassberg, Novartis Pharmaceuticals Corporation (E);
Mitchell Jackson, Alcon (C), Allergan (C), Bausch and Lomb (C), Blephex (C), Bruder (C), Eyevance Pharmaceuticals (C), Johnson & Johnson (C), Kala (C), Novartis (C), Ocular Therapeutix (C), OysterPoint (C), Quidel (C), SightSciences (C), Sun Pharmaceutical Industries (C), TearLab (C)